Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Sun Pharma Announces Settlement of Patent Litigation for Generic Revlimid (lenalidomide) in US

    Sun Pharmaceutical Industries Limited along with one of its wholly owned subsidiaries announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid® (lenalidomide capsules) in the US.

  • LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

    Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.

  • Zydus and Bayer announce continuity of their successful Joint Venture

    Bayer Pte Ltd and Cadila Healthcare Limited announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.

  • Pharma Conclave 2021 – Innovations in Pharmaceutical Sciences and Management

    IIHMR University, Jaipur as a leading healthcare institution which has its prime focus in generating talent pool that contributes immensely in the health sector organized Pharma Conclave 2021 that focused on ‘Innovations in Pharmaceutical Sciences and Management’. Dr. SD Gupta, Trustee Secretary, IIHMR University, Chief Guest, Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Former MD, Abbott Healthcare, and Dr. P R Sodani, President, IIHMR University were the eminent speakers.

  • New Technique Allows for Identification of Potential Drugs to Fight Resistant Bacteria

    Researchers from the Miami University in Ohio have optimized a new technique that will allow scientists to evaluate how potential inhibitors work on antibiotic-resistant bacteria. This technique, called native state mass spectrometry, provides a quick way for scientists to identify the best candidates for effective clinical drugs, particularly in cases where bacteria can no longer be treated with antibiotics alone. This research will be presented at the American Society for Microbiology World Microbe Forum online conference on June 21, 2021.

  • Human Reverse Transcriptase can Write RNA Sequences into DNA, Research

    Cells contain machinery that duplicates DNA into a new set that goes into a newly formed cell. That same class of machines, called polymerases, also build RNA messages, which are like notes copied from the central DNA repository of recipes, so they can be read more efficiently into proteins. But polymerases were thought to only work in one direction DNA into DNA or RNA. This prevents RNA messages from being rewritten back into the master recipe book of genomic DNA.

  • CSIR and Tata MD partners to augment COVID-19 testing

    The Council for Scientific and Industrial Research (CSIR), and Tata Medical and Diagnostics Ltd (Tata MD), the new healthcare venture from the Tata Group have teamed up to boost the COVID-19 testing capacity across Tier-II and Tier-III towns as well as rural areas, across India. The two organisations are developing capacity to handle any future surge in the COVID-19 testing requirements.

  • Empagliflozin approved in Europe for the treatment of heart failure

    Todays approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.

  • Anti-COVID drug Colchicine cleared for phase 2 clinical trials

    Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd., Hyderabad, have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients.

  • New alcohol-free sanitizer on the way

     An alcohol-free, aqueous, non-inflammable, and non-toxic hand sanitizer has been developed by a Pune-based start-up that will soon be available in the market. It is environment friendly and gentle on the hands and has been derived from silver nanoparticles.

Subscribe to Pharma News